RALLYBIO CORPORATION Interest and Other Income
RALLYBIO CORPORATION (RLYB) reported Interest and Other Income of $218.00 thousand for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-08-26
- RALLYBIO CORPORATION interest and other income for the quarter ending 2026-06-30 was $218.00K, a 58.32% decline year-over-year.
- RALLYBIO CORPORATION interest and other income for the quarter ending 2026-03-31 was $201.00K, a 68.79% decline year-over-year.
- RALLYBIO CORPORATION interest and other income for the quarter ending 2025-12-31 was $560.00K, a 30.95% decline year-over-year.
- RALLYBIO CORPORATION interest and other income for the quarter ending 2025-09-30 was $462.00K, a 53.14% decline year-over-year.
- RALLYBIO CORPORATION interest and other income for fiscal 2023 was $6.15M, a 213.14% increase from fiscal 2022.
- RALLYBIO CORPORATION interest and other income for fiscal 2022 was $1.96M, a 3535.19% increase from fiscal 2021.
- RALLYBIO CORPORATION interest and other income for fiscal 2021 was $54.00K, a 68.42% decline from fiscal 2020.
- RALLYBIO CORPORATION interest and other income for fiscal 2020 was $171.00K.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $218.00K S-4/A · filed 2026-08-26 | $419.00K S-4/A · filed 2026-08-26 | $979.00K derived: sum of 3 quarters · filed 2026-08-26 | $1.44M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $201.00K S-4 · filed 2026-07-15 | $761.00K derived: sum of 2 quarters · filed 2026-08-26 | $1.22M derived: sum of 3 quarters · filed 2026-08-26 | $1.75M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $560.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $1.02M derived: sum of 2 quarters · filed 2026-08-26 | $1.54M derived: sum of 3 quarters · filed 2026-08-26 | $2.19M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $462.00K 10-Q · filed 2025-11-06 | $985.00K derived: sum of 2 quarters · filed 2026-08-26 | $1.63M 10-Q · filed 2025-11-06 | $2.44M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $523.00K S-4/A · filed 2026-08-26 | $1.17M S-4/A · filed 2026-08-26 | $1.98M derived: sum of 3 quarters · filed 2026-08-26 | $2.96M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $644.00K S-4 · filed 2026-07-15 | $1.46M derived: sum of 2 quarters · filed 2026-08-26 | $2.44M derived: sum of 3 quarters · filed 2026-08-26 | $3.58M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | $811.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $1.80M derived: sum of 2 quarters · filed 2026-08-26 | $2.94M derived: sum of 3 quarters · filed 2026-08-26 | $4.22M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $986.00K 10-Q · filed 2025-11-06 | $2.13M derived: sum of 2 quarters · filed 2025-11-06 | $3.40M 10-Q · filed 2025-11-06 | $4.85M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.14M 10-Q · filed 2025-08-07 | $2.42M 10-Q · filed 2025-08-07 | $3.87M derived: sum of 3 quarters · filed 2025-08-07 | $5.41M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.28M 10-Q · filed 2025-05-08 | $2.72M derived: sum of 2 quarters · filed 2025-05-08 | $4.27M derived: sum of 3 quarters · filed 2025-05-08 | $5.88M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $2.99M derived: sum of 2 quarters · filed 2025-03-13 | $4.60M derived: sum of 3 quarters · filed 2025-03-13 | $6.15M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.54M 10-Q · filed 2024-11-07 | $3.15M derived: sum of 2 quarters · filed 2024-11-07 | $4.70M 10-Q · filed 2024-11-07 | $5.77M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.61M 10-Q · filed 2024-08-08 | $3.15M 10-Q · filed 2024-08-08 | $4.22M derived: sum of 3 quarters · filed 2024-08-08 | $4.75M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.55M 10-Q · filed 2024-05-09 | $2.62M derived: sum of 2 quarters · filed 2024-05-09 | $3.14M derived: sum of 3 quarters · filed 2024-05-09 | $3.41M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.60M derived: sum of 2 quarters · filed 2024-03-12 | $1.87M derived: sum of 3 quarters · filed 2024-03-12 | $1.96M 10-K · filed 2024-03-12 |
| 2022-09-30 | $525.00K 10-Q · filed 2023-11-09 | $795.00K derived: sum of 2 quarters · filed 2023-11-09 | $892.00K 10-Q · filed 2023-11-09 | $904.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $270.00K 10-Q · filed 2023-08-08 | $367.00K 10-Q · filed 2023-08-08 | $379.00K derived: sum of 3 quarters · filed 2023-08-08 | $391.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $97.00K 10-Q · filed 2023-05-09 | $109.00K derived: sum of 2 quarters · filed 2023-05-09 | $121.00K derived: sum of 3 quarters · filed 2023-05-09 | $134.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $24.00K derived: sum of 2 quarters · filed 2023-03-06 | $37.00K derived: sum of 3 quarters · filed 2023-03-06 | $54.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $12.00K 10-Q · filed 2022-11-07 | $25.00K derived: sum of 2 quarters · filed 2022-11-07 | $42.00K 10-Q · filed 2022-11-07 | $69.00K derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $13.00K 10-Q · filed 2022-08-08 | $30.00K 10-Q · filed 2022-08-08 | $57.00K derived: sum of 3 quarters · filed 2022-08-08 | $99.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $17.00K 10-Q · filed 2022-05-10 | $44.00K derived: sum of 2 quarters · filed 2022-05-10 | $86.00K derived: sum of 3 quarters · filed 2022-05-10 | $133.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $69.00K derived: sum of 2 quarters · filed 2022-03-15 | $116.00K derived: sum of 3 quarters · filed 2022-03-15 | $171.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | $42.00K 10-Q · filed 2021-11-10 | $89.00K derived: sum of 2 quarters · filed 2021-11-10 | $144.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $47.00K 10-Q · filed 2021-09-09 | $102.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |